title: Multiple vaccinations: friend or foe.
abstract: Few immunotherapists would accept the concept of a single vaccination inducing a therapeutic anticancer immune response in a patient with advanced cancer. But what is the evidence to support the "more-is-better" approach of multiple vaccinations? Because we are unaware of trials comparing the effect of a single vaccine versus multiple vaccinations on patient outcome, we considered that an anticancer immune response might provide a surrogate measure of the effectiveness of vaccination strategies. Because few large trials include immunologic monitoring, the majority of information is gleaned from smaller trials in which an evaluation of immune responses to vaccine or tumor, before and at 1 or more times following the first vaccine, was performed. In some studies, there is convincing evidence that repeated administration of a specific vaccine can augment the immune response to antigens contained in the vaccine. In other settings, multiple vaccinations can significantly reduce the immune response to 1 or more targets. Results from 3 large adjuvant vaccine studies support the potential detrimental effect of multiple vaccinations as clinical outcomes in the control arms were significantly better than that for treatment groups. Recent research has provided insights into mechanisms that are likely responsible for the reduced responses in the studies noted above, but supporting evidence from clinical specimens is generally lacking. Interpretation of these results is further complicated by the possibility that the dominant immune response may evolve to recognize epitopes not present in the vaccine. Nonetheless, the Food and Drug Administration approval of the first therapeutic cancer vaccine and recent developments from preclinical models and clinical trials provide a substantial basis for optimism and a critical evaluation of cancer vaccine strategies.
authors.affiliation: Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland Medical Center, USA.
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Church
authors.forename: Shawn M
authors.initials: SM
authors.lastname: Jensen
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Twitty
authors.forename: Keith
authors.initials: K
authors.lastname: Bahjat
authors.forename: Hong-Ming
authors.initials: HM
authors.lastname: Hu
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Urba
authors.forename: Bernard A
authors.initials: BA
authors.lastname: Fox
mesh_terms: D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology* / Q000627:therapeutic use; D000939:Epitopes; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D008545:Melanoma / Q000473:pathology / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D022223:Vaccines, Subunit / Q000276:immunology / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D000939:Epitopes; D022223:Vaccines, Subunit; D016178:Granulocyte-Macrophage Colony-Stimulating Factor